Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 24;65(6):4854-4864.
doi: 10.1021/acs.jmedchem.1c02040. Epub 2022 Mar 15.

The Mechanism of Action of Hepatitis B Virus Capsid Assembly Modulators Can Be Predicted from Binding to Early Assembly Intermediates

Affiliations

The Mechanism of Action of Hepatitis B Virus Capsid Assembly Modulators Can Be Predicted from Binding to Early Assembly Intermediates

Anna Pavlova et al. J Med Chem. .

Abstract

Interfering with the self-assembly of virus nucleocapsids is a promising approach for the development of novel antiviral agents. Applied to hepatitis B virus (HBV), this approach has led to several classes of capsid assembly modulators (CAMs) that target the virus by either accelerating nucleocapsid assembly or misdirecting it into noncapsid-like particles, thereby inhibiting the HBV replication cycle. Here, we have assessed the structures of early nucleocapsid assembly intermediates, bound with and without CAMs, using molecular dynamics simulations. We find that distinct conformations of the intermediates are induced depending on whether the bound CAM accelerates or misdirects assembly. Specifically, the assembly intermediates with bound misdirecting CAMs appear to be flattened relative to those with bound accelerators. Finally, the potency of CAMs within the same class was studied. We find that an increased number of contacts with the capsid protein and favorable binding energies inferred from free energy perturbation calculations are indicative of increased potency.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure

Drs. Schinazi, Amblard and Bassit along with Emory University are entitled to equity and royalties related to products licensed to Aligos Therapeutics, Inc. being further evaluated in the research described in this paper. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies.

Figures

Figure 1:
Figure 1:
HBV capsid structure and assembly. (A) Structure of Cp149 dimer taken from the capsid structure (PDB code 3J2V). The names of helices α1–5 are indicated; yellow and green helices form the assembly interface, while the dimerization interface helices, α3-α4, are colored blue and purple respectively. (B) Overlap of GLS4 and AT130 binding sites after alignment of the bound protein structures (PDB codes 5E0I and 4G93, respectively). Both compounds occupy a similar space in the HAP pocket and interact with Trp102. (C) HBV capsid assembly process based on experimental data and mathematical modeling.,–
Figure 2:
Figure 2:
Comparison of standard deviation ellipses (SDEs) for spike and base angle distributions for selected simulations. SDEs are centered on the average values of a distribution. Their width and height are based on the standard deviation of the corresponding variables, while their rotation is based on the correlation between two variables. The ellipses shown here are scaled to envelop 90% of the sampled distributions. The locations of the starting structures in the graphs are shown in Figure S9. With the exception of Hexa SDE, all other SDEs are for tetramer structures. (A) SDEs of base and spike angles for the simulated apo structures and for PPA compounds, which accelerate assembly. (B) SDEs of base and spike angles for selected bound misdirecting CAMs. (C) SDEs of base and spike angles for SBAs, which do not alter the empty capsid assembly, and GLPs, which cause formation of misformed capsids. In (B) and (C) the results for the apo tetramer and hexamer are added for comparison. (D) Definitions of spike and base angles. See Methods and Supporting Information for details.
Figure 3:
Figure 3:
Standard deviation ellipses for hexamers with one bound GLS4, GLP-26, or AT130. Apo hexamer is added for comparison.
Figure 4:
Figure 4:
Selected snapshots of tetramers from our simulations illustrate the effect of spike and base angles on the curvature of the assembly intermediates. See Figure 2D for base and spike definitions. θb and θs correspond to the values of base and spike angles for each structure, respectively. Increases in either spike or base angle induce more curvature in the tetramer structures, with the most curved structures having large base and spike angles.
Figure 5:
Figure 5:
Comparison of hydrogen bonding with HBV capsid protein between GLP/SBA derivatives, and HAP compounds. Hydrogens are omitted for clarity. The CAM is colored in green and protein residues are colored in cyan. (A) Hydrogen bonding with GLS4. (B) Hydrogen bonding with GLP-26.
Figure 6:
Figure 6:
Setup and results of our FEP calculations. The structural differences from HAP12 are shown in red. All differences in binding free energies are shown in kcal/mol. Black values were calculated from experimental EC50s from Table 4 using Eq. 1, while blue values were obtained from FEP calculations.

References

    1. Schweitzer A; Horn J; Mikolajczyk RT; Krause G; Ott JJ Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015, 386, 1546–1555. - PubMed
    1. Deres K; Schröder CH; Paessens A; Goldmann S; Hacker HJ; Weber O; Krämer T; Niewöhner U; Pleiss U; Stoltefuss J; Graef E; Koletzki D; Masantschek RNA; Reimann A; Jaeger R; Gross R; Beckermann B; Schlemmer K-H; Haebich D; Rübsamen-Waigmann H Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003, 299, 893–896. - PubMed
    1. Bourne C; Lee S; Venkataiah B; Lee A; Korba B; Finn MG; Zlotnick A Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle. J. Virol. 2008, 82, 10262–10270. - PMC - PubMed
    1. Delaney WE; Edwards R; Colledge D; Shaw T; Furman P; Painter G; Locarnini S Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob. Agents Chemother. 2002, 46, 3057–3060. - PMC - PubMed
    1. Feld JJ; Colledge D; Sozzi V; Edwards R; Littlejohn M; Locarnini SA The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res. 2007, 76, 168–177. - PubMed

Publication types